Novo Nordisk (NVO) introduced Saturday that its FDA-approved weight reduction remedy Wegovy, often known as semaglutide, led to cardiovascular advantages no matter age, gender, ethnicity, and weight problems degree in a Phase 3 trial.
In August, the Danish drugmaker mentioned that the trial known as SELECT achieved its major objective because the GLP-1 receptor agonist at 2.4 mg led to a 20% threat discount from main antagonistic cardiovascular occasions (MACE) akin to stroke with a statistically vital impact.
Announcing its detailed outcomes at a medical occasion organized by the American Heart Association (AHA), the corporate mentioned that the danger discount in MACE was seen no matter sufferers’ age, gender, ethnicity, and beginning physique mass index (BMI).
The advantages had been seen quickly after beginning the remedy, which, based on the corporate, signifies that there won’t be a connection between the drug’s weight reduction results and its cardiovascular advantages.
The international examine enrolled greater than 17K overweight or obese adults with heart problems and no prior historical past of diabetes.
Other highlights of the trial point out that semaglutide, in comparison with placebo, led to a statistically vital 28% threat discount in coronary heart assaults.
However, findings a few 7% threat discount in non-fatal strokes and a 15% threat discount in cardiovascular loss of life weren’t statistically vital.
Novo (NVO) mentioned that the semaglutide 2.4 mg dose in SELECT appeared secure and demonstrated a tolerability profile in step with prior research.
The firm expects the U.S. and EU to determine subsequent yr on its bid to increase semaglutide labeling to incorporate a sign for cardiovascular threat discount.